Clinical trials: Antiviral Treatment
Acquired Immune Deficiency Syndrome, AIDS
Pilot Study of a Raltegravir Based NRTI Sparing Regimen
This pilot study will provide data on the safety and efficacy of the combination of Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced subjects that have a suppressed HIV viral load on a…
- Conditions
- Acquired Immune Deficiency Syndrome, AIDS, Human Immunodeficiency Virus, HIV Infections
- Trial name
- NCT00814879
- Testing
- Raltegravir, Atazanavir, Standard treatment regimen
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Yale University
Hepatitis C
A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study
A follow-up study to assess resistance and durability of response to 3 experimental drugs ABT-450/r, ABT-267, and ABT-333 in participants who have participated in AbbVie Phase 2 or 3 clinical studies with these agents for the…
- Trial name
- NCT01773070
- Testing
- ABT-450/ritonavir, ABT-333, ABT-267
- Volunteers
- 478 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C
Hepatitis C Antiviral Resistance in African-Americans
This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not…
- Trial name
- NCT00038974
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 8 sites in United States
- Volunteers
- 401 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants
The primary objectives of this study are to evaluate the safety, tolerability and steady-state PK and confirm the dose of EVG/r in HIV-1 infected, antiretroviral treatment-experienced children 4 weeks to <18 years of age.
- Trial name
- NCT01923311
- Testing
- EVG, Background regimen
- Where
- 11 sites in United States, Italy and 4 more
- Volunteers
- 31 people
- Sponsor
- Gilead Sciences
HCV Coinfection, Hepatitis C
Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens
The aim of this study is to evaluate RBV plasma concentrations when used in combination with newly developed DAA combinations. If possible, its correlations with SVR rates and incidence of anaemia will be assessed in HCV-patients.
- Trial name
- RIBACOP (NCT02505243)
- Where
- Netherlands
- Volunteers
- 252 people
- Sponsor
- Radboud University Medical Center
HIV
HIV-DNA Dynamics in HIV Monoinfected or HIV/HCV Coinfected Patients
New markers of viral activity are now under investigation. Aim of the study is to investigate the efficacy of new antiretroviral drugs by monitoring HIV-DNA dynamics in HIV-positive population.
- Trial name
- ViDyMoCo (NCT02836782)
- Testing
- Blood sample withdrawal
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Catholic University of the Sacred Heart
Anogenital Warts, Condylomata Acuminata
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
The purpose of this study is to determine the safety, tolerability and efficacy of the topical application of AP611074 5% gel during 6 weeks on ano-genital warts caused by human papillomavirus (HPV).
- Conditions
- Anogenital Warts, Condylomata Acuminata, Human Papillomavirus Infection
- Trial name
- NCT01532102
- Testing
- AP611074
- Where
- 4 sites in Argentina, France
- Volunteers
- 24 people
- Sponsor
- Anaconda Pharma
Respiratory Syncytial Virus (RSV) Infection
Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study
The primary purpose of this study is to evaluate the antiviral activity of oral BTA-C585 compared to placebo in healthy volunteers after intranasal challenge with RSV-A Memphis 37b virus.
- Trial name
- NCT02718937
- Testing
- BTA-C585 oral capsule
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Biota Pharma Europe Limited
HIV-1-infection
Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)
The purpose of this study is to demonstrate the effectiveness of Symtuza® in a rapid reinitiation model of care in patients with HIV-1 infection and who are treatment-experienced but have been off of antiretroviral therapy (ART)…
- Trial name
- ReSTART (NCT04388904)
- Testing
- Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- The Crofoot Research Center, Inc.
Hepatitis C, Chronic
A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response
This Registry is designed to obtain long term data on participants who have failed to achieve sustained virologic response (SVR) while receiving at least one Gilead oral antiviral agent (OAV) in a previous Gilead-sponsored…
- Trial name
- NCT01457768
- Where
- 323 sites in United States, Australia and 14 more
- Volunteers
- 570 people
- Sponsor
- Gilead Sciences
Hepatitis C
Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C
Investigation of the effects of the new Abbvie direct acting anti-viral (DAA) treatment of chronic viral hepatitis C infection on the macrophage specific activation marker soluble CD163, portal hypertension determined by the…
- Trial name
- NCT02526641
- Testing
- Functional Hepatic Nitrogen Clearance (FHNC), Galactose Elimination Capacity (GEC), Liver vein catheterization
- Where
- Denmark
- Volunteers
- 16 people
- Sponsor
- University of Aarhus
Chronic Hepatitis B
Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy
Background and aims: Nucleos(t)ide analogues may suppress HBV DNA to undetectable level, but only about 30-40% remain sustained response 1-3 years after discontinued therapy.
- Trial name
- NCT02505009
- Testing
- Engerix-B, Tenofovir, Entecavir
- Where
- Taiwan
- Volunteers
- 116 people
- Sponsor
- Chang Gung Memorial Hospital
Chronic Hepatitis C Infection
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
The study is designed to provide long term clinical and virologic follow up in subjects infected with hepatitis C virus (HCV) who received interferon-based therapy or direct-acting antiviral agents (DAAs)-based therapy.
- Trial name
- NCT02578693
- Where
- 3 sites in China, Japan
- Volunteers
- 1,210 people
- Sponsor
- Humanity and Health Research Centre
Hepatitis B, Chronic
A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection
This randomized, multicenter, partially double-blind, placebo-controlled study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antiviral effects of treatment with RO6864018 in…
- Trial name
- NCT02391805
- Testing
- Entecavir, RO6864018, Tenofovir
- Where
- 14 sites in Hong Kong, Malaysia and 4 more
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C
The purposes of the PLUS study were to confirm the safety and tolerability of two doses of LocteronTM (320 ug and 640 ug) dosed over four weeks in patients who had failed prior anti-HCV therapies (Panels A and B), and then to…
- Trial name
- PLUS (NCT00593151)
- Testing
- Locteron (controlled-release interferon alpha 2b), pegylated IFNa2b
- Where
- 5 sites in United States
- Volunteers
- 32 people
- Sponsor
- Biolex Therapeutics, Inc.
Hepatitis C, HIV
Control and Elimination Within Australia of Hepatitis C From People Living With HIV
The purpose of this study is to evaluate the feasibility of rapid scale-up of new hepatitis C (HCV) treatments, known as interferon-free Direct Acting Antiviral (DAA) drugs, and impact on the proportion of people with HCV within…
- Conditions
- Hepatitis C, HIV, HIV-HCV Coinfection
- Trial name
- CEASE (NCT02102451)
- Where
- 18 sites in Australia
- Volunteers
- 492 people
- Sponsor
- Kirby Institute
Influenza, Pneumonia
Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Current guidelines recommend early initiation of empiric antibiotic therapy to cover typical and atypical bacteria that may cause community-acquired pneumonia (CAP).
- Trial name
- RETOS (NCT01248715)
- Testing
- oseltamivir
- Where
- 5 sites in United States
- Volunteers
- 1,107 people
- Sponsor
- University of Louisville
Hepatitis B, Chronic
Discontinuation of Antiviral Therapy as a Strategy to Cure Hepatitis B
Cirrhosis or cancer of the liver caused by hepatitis B virus (HBV) are major global health problems. Chronic HBV infection has become more common in Sweden with immigration.
- Trial name
- STOP-B (NCT05328427)
- Testing
- Stopping
- Where
- Sweden
- Volunteers
- 33 people
- Sponsor
- Göteborg University
HIV Infections
A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease
To assess the safety and to evaluate the anti-HIV effect of low-, moderate-, and high-dose schedules of zidovudine (AZT) plus didanosine (ddI) versus ddI alone in asymptomatic HIV-infected patients.
- Trial name
- NCT00000656
- Testing
- Zidovudine, Didanosine
- Where
- 5 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Virus
The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects
This study seeks to assess the durability of response and persistence of resistance to ombitasvir/ paritaprevir/ritonavir in Japanese participants who enrolled in a Phase 2 or 3 clinical study with these agents for the treatment…
- Trial name
- NCT02581020
- Where
- 53 sites in Japan
- Volunteers
- 344 people
- Sponsor
- AbbVie